ACOR News and Press, Acorda Therapeutics Inc. From 10/16/22

$16.5 million to recover past royalties and interest Cessation of double-digit royalty/supply payments Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that a three-judge arbitration panel has issued a final decision in a dispute with Alkermes PLC (Nasdaq...

Acorda Therapeutics ( NASDAQ: ACOR ) said it withdrew a proposal  requesting to increase the number of company's authorized shares. The company is scheduled to hold a special meeting of stockholders on Nov. 4, where several proposals would be put to vote. Mean...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the company has withdrawn Proposal One, a request to increase the number of authorized shares of Acorda stock, from the ballot for the Special Meeting of Stockholders scheduled for November 4, 2022. Proposal Two, authoriz...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will be presenting at the H.C. Wainwright 24 th Annual Global Investment Conference on Monday, September 12 at 3 p.m. ET. The conference will be conduc...

Summary Using its animal models, Biocytogen has also developed an innovative in vivo drug efficacy and safety screening process to discover 10+ preclinical and clinical candidates, a collection of monoclonal antibodies, bispecific antibodies and bispecific ADCs. I-Mab said it woul...

Commercial-stage biopharmaceutical company Acorda Therapeutics ( NASDAQ: ACOR ) announced a license agreement with Chinese biotech Asieris Pharmaceuticals on Monday for the preclinical candidate, Nepicastat. Per the terms, the two companies will collaborate to develop Nepi...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a biotechnology company headquartered in China. Under the terms of the agreement, Acorda will receive an upf...

Acorda Therapeutics ( NASDAQ: ACOR ) has announced that Lauren Sabella, Chief Operating Officer , will resign from the Co. effective Sept. 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. Ms. Sabellaȁ...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. “We are grateful...

Acorda Therapeutics, Inc. (ACOR) Q2 2022 Results Conference Call August 04, 2022 04:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - CEO Mike Gesser - CFO Presentation Operator Ladies and gentlemen, w...